Outcome measures in ANCA-associated vasculitis.
The outcome in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis has considerably improved with the use of potent immunosuppression. In the most severe cases, mortality remains an important risk despite aggressive intervention. However, for most patients who survive, quali...
Auteurs principaux: | Suppiah, R, Robson, J, Luqmani, R |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2010
|
Documents similaires
-
Cardiovascular outcomes in ANCA associated vasculitis
par: Mukhtyar, C, et autres
Publié: (2008) -
Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
par: Suppiah, R, et autres
Publié: (2011) -
The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.
par: Merkel, P, et autres
Publié: (2011) -
Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
par: Suppiah, R, et autres
Publié: (2011) -
THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
par: Suppiah, R, et autres
Publié: (2011)